Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1947 2
1948 2
1949 5
1950 4
1952 2
1953 1
1954 1
1956 2
1957 2
1958 4
1959 2
1960 3
1961 3
1962 3
1964 2
1965 1
1967 6
1968 3
1969 6
1970 3
1971 3
1972 4
1973 3
1975 3
1976 10
1977 3
1978 2
1979 6
1980 7
1981 4
1982 4
1983 11
1984 12
1985 12
1986 17
1987 17
1988 36
1989 22
1990 30
1991 35
1992 32
1993 30
1994 30
1995 34
1996 13
1997 26
1998 25
1999 25
2000 22
2001 25
2002 32
2003 24
2004 21
2005 38
2006 34
2007 40
2008 38
2009 41
2010 49
2011 51
2012 57
2013 56
2014 35
2015 41
2016 57
2017 59
2018 42
2019 43
2020 47
2021 24
Text availability
Article attribute
Article type
Publication date

Search Results

1,295 results
Results by year
Filters applied: . Clear all
Page 1
A decade of clinical development of PARP inhibitors in perspective.
Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS. Mateo J, et al. Among authors: kaye sb. Ann Oncol. 2019 Sep 1;30(9):1437-1447. doi: 10.1093/annonc/mdz192. Ann Oncol. 2019. PMID: 31218365 Free PMC article. Review.
Pseudomonas aeruginosa and microbial keratitis.
Hilliam Y, Kaye S, Winstanley C. Hilliam Y, et al. Among authors: kaye s. J Med Microbiol. 2020 Jan;69(1):3-13. doi: 10.1099/jmm.0.001110. J Med Microbiol. 2020. PMID: 31750813 Review.
Rethinking ovarian cancer: recommendations for improving outcomes.
Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR. Vaughan S, et al. Among authors: kaye sb. Nat Rev Cancer. 2011 Sep 23;11(10):719-25. doi: 10.1038/nrc3144. Nat Rev Cancer. 2011. PMID: 21941283 Free PMC article.
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.
de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA. de Bono J, et al. Among authors: kaye s. Cancer Discov. 2017 Jun;7(6):620-629. doi: 10.1158/2159-8290.CD-16-1250. Epub 2017 Feb 27. Cancer Discov. 2017. PMID: 28242752 Free PMC article. Clinical Trial.
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.
Mateo J, Moreno V, Gupta A, Kaye SB, Dean E, Middleton MR, Friedlander M, Gourley C, Plummer R, Rustin G, Sessa C, Leunen K, Ledermann J, Swaisland H, Fielding A, Bannister W, Nicum S, Molife LR. Mateo J, et al. Among authors: kaye sb. Target Oncol. 2016 Jun;11(3):401-15. doi: 10.1007/s11523-016-0435-8. Target Oncol. 2016. PMID: 27169564 Free article. Clinical Trial.
BMJ Open Ophthalmology.
Kaye SB. Kaye SB. BMJ Open Ophthalmol. 2020 Sep 1;5(1):e000530. doi: 10.1136/bmjophth-2020-000530. eCollection 2020. BMJ Open Ophthalmol. 2020. PMID: 32923680 Free PMC article. No abstract available.
1,295 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page